Managed Healthcare Executive conducted its annual pharmacy survey, capturing perspectives from payers, pharmacy leaders, health systems, academic institutions, government and pharmacy benefit managers (PBMs).

Obesity drugs are advancing with over 100 drugs in development. New treatments combining GLP-1 with other hormones are being developed.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.